Erasca: Funding, Investors & Team (Sep 2026)
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.
Erasca has raised $395M across 3 funding rounds on record, the most recent an undisclosed round of $259M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Erasca Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Erasca Funding Rounds
Erasca raised $36.0M in an undisclosed round announced in Aug 2020.
2.3 years later, an undisclosed round of $100M was announced in Dec 2022.
3.1 years later, an undisclosed round of $259M was announced in Jan 2026.
Erasca Founders and Leadership Team
No contact details are on record for this team yet.
Erasca Funding Compared to Other Biotechnology Startups
Erasca's latest round of $259M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Erasca in Biotechnology and San Diego
Companies Similar to Erasca
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Erasca Funding FAQs
What does Erasca do?
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.
How much funding has Erasca raised?
Erasca has raised $395M across 3 rounds on record. The most recent is an undisclosed round of $259M announced in Jan 2026.
When did Erasca last raise funding?
Erasca's most recent funding round on record is an undisclosed round of $259M, announced in Jan 2026.
Who is the CEO of Erasca?
Jonathan L is listed as CEO at Erasca.
Where is Erasca headquartered?
Erasca is based in San Diego, California, United States.
How many employees does Erasca have?
Erasca is in the 101-250 employee band.
How does Erasca's funding compare to other Biotechnology startups?
Erasca's latest round of $259M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Erasca Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Erasca is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.